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ORIGINAL INVESTIGATION
Hyperglycemia and risk of ventricular 
tachycardia among patients hospitalized 
with acute myocardial infarction
Hoang V. Tran1,4, Joel M. Gore2, Chad E. Darling3, Arlene S. Ash1, Catarina I. Kiefe1 and Robert J. Goldberg1*
Abstract 
Background: Little is known about the association of hyperglycemia with the development of ventricular tachy-
cardia (VT) in patients hospitalized with acute myocardial infarction (AMI) which we examined in the present study. 
The objectives of this community-wide observational study were to examine the relation between elevated serum 
glucose levels at the time of hospital admission for AMI and occurrence of VT, and time of occurrence of VT, during 
the patient’s acute hospitalization.
Methods: We used data from a population-based study of patients hospitalized with AMI at all central Massachusetts 
medical centers between 2001 and 2011. Hyperglycemia was defined as a serum glucose level ≥ 140 mg/dl at the 
time of hospital admission. The development of VT was identified from physicians notes and electrocardiographic 
findings by our trained team of data abstractors.
Results: The average age of the study population was 70 years, 58.0% were men, and 92.7% were non-Hispanic 
whites. The mean and median serum glucose levels at the time of hospital admission were 171.4 mg/dl and 143.0, 
respectively. Hyperglycemia was present in 51.9% of patients at the time of hospital admission; VT occurred in 652 
patients (15.8%), and two-thirds of these episodes occurred during the first 48 h after hospital admission (early VT). 
After multivariable adjustment, patients with hyperglycemia were at increased risk for developing VT (adjusted 
OR = 1.48, 95% CI = 1.23–1.78). The presence of hyperglycemia was significantly associated with early (multivariable 
adjusted OR = 1.39, 95% CI = 1.11–1.73) but not with late VT. Similar associations were observed in patients with and 
without diabetes and in patients with and without ST-segment elevation AMI.
Conclusions: Efforts should be made to closely monitor and treat patients who develop hyperglycemia, especially 
early after hospital admission, to reduce their risk of VT.
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Introduction
Ventricular tachycardia frequently complicates the clini-
cal course of patients hospitalized with acute myocardial 
infarction and is associated with worse in-hospital and 
long-term outcomes, especially sudden cardiac death 
[1, 2]. The development of ventricular tachycardia (VT) 
in patients with an acute myocardial infarction (AMI) is 
typically associated with a larger infarct, ST segment ele-
vation, left ventricular dysfunction, and more extensive 
underlying coronary artery disease [3, 4].
During the early stages of AMI, the sympathetic 
nervous system responds to physiological and emo-
tional stress by releasing noradrenalin, and serum glu-
cose levels typically increase shortly in response to this 
sympathetic stimulation [5]. The hyperglycemic state 
can directly alter cardiac electrophysiological status 
by prolonging the QT-interval, thereby increasing the 
risk of VT and other serious cardiac arrhythmias [6]. 
In addition, hyperglycemia is associated with a larger 
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infarct size [7], impaired microvascular circulation 
[8], and worse left ventricular function [9], which can 
independently promote electrical instability. Few stud-
ies, however, have examined the association between 
serum glucose levels at the time of hospital admission 
and occurrence of VT after an AMI [10–12]. Moreover, 
these studies have been limited by their small sample 
size, have examined the occurrence of VT with other 
cardiac arrhythmias which may not share the same 
underlying mechanisms, or have not examined the time 
of onset of VT in relation to elevated blood glucose lev-
els [10–13].
Using data from a large population-based surveillance 
study of patients hospitalized with independently con-
firmed AMI at all 11 central Massachusetts medical cent-
ers, we examined the association between serum glucose 
levels at the time of hospital admission and the develop-
ment of VT during the patient’s acute hospitalization.
Methods
Study design and data collection
We used data from the Worcester Heart Attack Study, an 
ongoing population-based clinical/epidemiologic inves-
tigation that is examining long-term trends in the inci-
dence, hospital, and post-discharge case-fatality rates of 
AMI among residents of the Worcester, Massachusetts, 
metropolitan area hospitalized at all 11 medical centers 
throughout central Massachusetts for this investigation 
[14–16]. In brief, the medical records of patients hospi-
talized for possible AMI at the 11 medical centers serv-
ing residents of central Massachusetts were individually 
reviewed and the diagnosis of AMI was independently 
validated according to criteria developed by the World 
Health Organization; patients were further classified 
into those with an ST-segment elevation AMI (STEMI) 
or Non-ST segment elevation AMI (NSTEMI) [17]. This 
investigation was approved by the Institutional Review 
Board at the University of Massachusetts Medical School.
Trained nurses and physicians abstracted demographic, 
clinical, and treatment data from the medical records 
of patients hospitalized with a confirmed AMI [14–16]. 
Abstracted information included: patient’s age, sex, med-
ical history, physiologic factors, laboratory test results at 
the time of hospital admission, length of hospital stay, 
and the in-hospital use of important cardiac medications 
and procedures (coronary angiography, percutaneous 
coronary intervention (PCI), and coronary artery bypass 
graft (CABG) surgery). Development of several signifi-
cant clinical complications (e.g., atrial fibrillation, car-
diogenic shock, stroke, heart failure) during the patient’s 
index hospitalization were identified using standardized 
clinical criteria [18–20].
Ventricular tachycardia
Ventricular tachycardia was defined as a cardiac arrhyth-
mia of three or more consecutive complexes originating 
from the ventricles at a rate of greater than 100 beats per 
minute [21]. We included both sustained VT (lasting 30 s 
or more) and nonsustained VT (lasting less than 30 s) due 
to similar risk of adverse cardiovascular outcomes asso-
ciated with both these types of VT [22]. The occurrence 
of VT was based on physicians’ progress notes and our 
research physicians also reviewed patients’ hospital ECG 
strips for purposes of identifying ECG changes consist-
ent with the development of VT. For patients with mul-
tiple episodes of VT, only the first episode was counted. 
Patients were classified as having either early VT, defined 
as occurring within 48 h after hospital admission, or late 
(occurring after 48 h) VT.
Serum glucose levels
Glucose levels were measured from blood samples drawn 
at the time of admission to the emergency department of 
all participating medical centers as part of their standard 
workup of hospitalized patients. All blood tests followed 
a standardized protocol in the laboratories at each par-
ticipating hospital.
Prior studies that have examined the prognostic impact 
of admission serum glucose levels have used different 
thresholds to define hyperglycemia [23, 24]. For purposes 
of this study, we defined hyperglycemia as a serum glu-
cose level ≥ 140 mg/dl, the cutoff suggested by the Amer-
ican Heart Association (AHA) for both diabetic and 
nondiabetic patients [25].
Study population
There were a total of 5783 patients hospitalized with a 
verified AMI at all central Massachusetts medical centers 
on a biennial basis between 2001 and 2011. We excluded 
from this pool of patients 84 patients who developed VT 
prior to hospital admission and 18 for whom the tim-
ing of VT could not be determined. We also excluded 
patients with missing data on age (n = 263), race 
(n = 187), heart rate (n = 100), blood pressure (n = 34), 
serum potassium (n = 42), glucose (n = 87), white blood 
cell count (n = 20), troponin I (n = 349), and serum cal-
cium (n = 450) findings, as well as length of hospital stay 
(n = 9). The final study sample consisted of 4140 patients 
with an independently confirmed AMI.
Data analysis
The baseline characteristics of patients who had serum 
glucose levels greater or less than 140 mg/dl were com-
pared using Chi Square tests for categorical variables and 
the t-test or Kruskal–Wallis test for continuous variables. 
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We used multivariable logistic regression modelling to 
examine the association between serum glucose levels 
at the time of hospital admission with the occurrence of 
VT, while controlling for several potentially confound-
ing demographic (age, sex, race) and clinical factors (past 
medical history, clinical presentation at admission, com-
plications during hospitalization, and in hospital treat-
ments). We a priori controlled for age, sex, and race in all 
regression models. Other variables were then iteratively 
tested and variables which changed the estimates of the 
effects of elevated serum glucose levels on the develop-
ment of VT by more than 10% were retained in the final 
regression models. After following these predetermined 
rules, we included age, sex, race, history of diabetes, type 
of AMI (STEMI vs. NSTEMI), and the in-hospital devel-
opment of heart failure in our multivariable adjusted 
models. We also carried out two subgroup analyses in 
which we examined the association between hyperglyce-
mia and VT in patients with a STEMI in comparison to 
those with an NSTEMI, and according to a history of dia-
betes as recorded in hospital medical records. Finally, we 
examined the association between serum glucose levels 
and VT in a dose response manner beginning at a serum 
glucose level of 120 mg/dl and increasing in increments 
of 20 mg/dl.
Results
Baseline patient characteristics
The average age of the study population was 70 (± 13.8) 
years, 58.0% were men, and 92.7% were non-Hispanic 
whites. The mean and median [inter quartile range 
(IQR)] serum glucose levels at the time of hospital admis-
sion were 171.4  mg/dl and 143.0 [116.0–203.0] mg/dl, 
respectively. Hyperglycemia, defined as a serum glucose 
level ≥ 140 mg/dl at the time of hospital admission, was 
present in 51.9% of hospitalized patients.
Patients with elevated serum glucose levels at the time 
of hospital admission for their independently confirmed 
AMI were approximately 5  years older and were more 
likely to be female than patients with serum glucose 
levels < 140  mg/dl (Table  1). Patients with hyperglyce-
mia were more likely to have been previously diagnosed 
with several important comorbidities (e.g., heart failure, 
chronic lung disease, chronic kidney disease, diabetes, 
and hypertension); these patients also had higher heart 
rate, serum potassium, and serum white blood cell count 
findings at the time of hospital presentation than patients 
with glucose levels < 140 mg/dl (Table 1). These patients 
were also more likely to have developed clinically signifi-
cant in-hospital complications (e.g., acute kidney injury, 
atrial fibrillation, heart failure, and cardiogenic shock) 
and were more likely to have received ACE-I/ARBs and 
anti-arrhythmic agents during their acute hospital stay 
compared with patients with lower serum glucose lev-
els. On the other hand, patients with hyperglycemia 
had lower systolic blood pressure and serum calcium 
findings at hospital presentation and were less likely to 
have received aspirin or lipid lowering agents or to have 
undergone a PCI during their index hospitalization.
Serum glucose levels and incidence of ventricular 
tachycardia
In our patient population, VT occurred in 652 patients 
(15.8%); for two-thirds of these patients (n = 434) their 
first episode occurred within 48 h of hospital admission. 
Overall, after adjusting for several demographic and clin-
ical variables of prognostic importance, patients admitted 
with serum glucose levels ≥ 140 mg/dl had an almost 50% 
higher odds of developing VT during their acute hospital 
stay than those with lower glucose levels (Table 2). This 
association was observed in the 434 patients who devel-
oped early VT (adjusted OR = 1.39, 95% CI = 1.11–1.73) 
whereas among the 218 patients whose VT developed 
at a later time (more than 48 h after hospital admission), 
the association between hyperglycemia and late onset 
VT was weaker and not statistically significant (adjusted 
OR = 1.19, 95% CI = 0.89–1.59). Adjusting for the hospi-
tal receipt of various cardiac interventions and medica-
tions did not materially affect the observed associations.
A history of diabetes was present in 36.1% of study 
patients. As expected, the mean and median [IQR] serum 
glucose levels were 224  mg/dl and 209 [147–283] mg/
dl among patients with previously diagnosed diabetes 
and 142 mg/dl and 129 [110–157] mg/dl among patients 
without a history of diabetes. However, the development 
of VT during the patient’s acute hospitalization was simi-
lar among patients with and without a history of diabetes 
(14.5% vs. 16.5%, respectively, p = 0.09); most events of 
VT in these patient populations occurred during the first 
48  h of hospital presentation (61.6% and 69.0%, respec-
tively, p = 0.06).
In examining the relationship between hyperglyce-
mia and VT further stratified according to the presence 
of previously diagnosed diabetes, patients with elevated 
serum glucose levels had a 40–70% higher odds of devel-
oping any VT or early VT compared with patients with 
lower serum glucose levels in those with and without a 
history of diabetes (Table 3).
Serum glucose levels were essentially similar for the 
1277 patients with STEMI and for the 2863 patients with 
an NSTEMI. The mean and median [IQR] serum glucose 
levels were 168 mg/dl and 144 [120–189] mg/dl, respec-
tively, in patients with a STEMI and 173 mg/dl and 143 
[114–210] mg/dl, respectively, in patients who had an 
NSTEMI (p = 0.46). However, VT developed significantly 
more often in patients with a STEMI than an NSTEMI 
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(22.0% vs. 13.0%, respectively, p < 0.001) and a signifi-
cantly greater proportion of VT episodes occurred dur-
ing the first 48  h of hospital admission in patients with 
a STEMI (78.7%) than among those with an NSTEMI 
(57.4%), (p < 0.001). Compared with patients who had 
lower serum glucose levels, patients who had elevated 
Table 1 Characteristics of  patients according to  serum glucose levels at  the  time of  hospital admission for  an  acute 
myocardial infarction
Italic values indicate significance of p value (p < 0.05)
IQR interquartile range, WBCC white blood cell count, ACE-I/ARBs angiotensin converting enzyme inhibitor/angiotensin II receptor blockers, CABG coronary artery 
bypass graft surgery
p-value from Chi square test and Fisher’s exact test for categorical variables and Wilcoxon rank-sum test for continuous variables
Characteristics < 140 mg/dl (n = 1949) ≥ 140 mg/dl (n = 2191) p-value
Age (median [IQR], years) 69 [57–81] 74 [63–82] < 0.001
Age (%) < 0.001
 < 55 20.7 11.9
 55–64 20.4 16.3
 65–74 20.2 23.9
 ≥ 75 38.8 48.0
Men (%) 62.0 54.4 < 0.001
White (%) 93.0 92.5 0.58
Medical history (%)
 Coronary artery disease 32.6 42.9 < 0.001
 Chronic lung disease 15.6 19.2 0.002
 Chronic kidney disease 16.5 24.3 < 0.001
 Diabetes 16.3 53.7 < 0.001
 Heart failure 17.1 28.1 < 0.001
 Hypertension 70.3 79.6 < 0.001
 Hypercholesterolemia 61.8 62.6 0.59
 Stable angina 13.9 15.3 0.23
 Stroke/transient ischemic attack 12.2 16.0 < 0.001
Findings at admission
 Pulse (median [IQR], beat/min) 78 [67–92] 88 [74–104] < 0.001
 Systolic blood pressure (median [IQR], mmHg) 141 [122–161] 140 [119–161] 0.18
 Troponin I (median [IQR], ng/ml) 0.51 [0.10–3.50] 0.50 [0.10–3.70] 0.72
 Potassium (median [IQR], mmol/l) 4.1 [3.8–4.5] 4.2 [3.9–4.7] < 0.001
 Calcium (median [IQR], mg/dl) 9.1 [8.7–9.5] 9.0 [8.7–9.4] 0.002
 WBCC (median [IQR],  109 cell/l) 8.9 [7.2–11.2] 10.4 [7.9–13.4] < 0.001
ST segment elevation 29.8 31.8 0.16
In hospital complications (%)
 Acute kidney injury 10.4 19.3 < 0.001
 Atrial fibrillation 16.7 22.1 < 0.001
 Cardiogenic shock 2.4 6.5 < 0.001
 Heart failure 25.9 45.5 < 0.001
Treatment during hospitalization (%)
 Aspirin 94.4 91.6 < 0.001
 ACE-I/ARBs 67.7 73.3 < 0.001
 Antiarrhythmic agents 14.6 18.9 < 0.001
 Beta blockers 92.3 90.9 0.10
 Lipid lowering agents 77.2 74.1 0.018
 Thrombolytic therapy 2.3 2.4 0.74
 Percutaneous coronary intervention 51.6 42.0 < 0.001
 CABG 7.1 6.9 0.80
Length of stay (median [IQR], days) 4 [2–6] 4 [3–7] < 0.001
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serum glucose levels had an approximate 30% higher 
multivariable adjusted odds of developing VT, regardless 
of the type of AMI (Table 3).
Lastly, we carried out an additional analysis in which 
we examined the association between baseline hospi-
tal serum glucose levels and the risk of developing VT, 
early VT, and late VT at varying serum glucose cut-offs, 
separately in patients with and without previously diag-
nosed diabetes (Table  4). As seen, patients with higher 
serum glucose levels were at greater risk for developing 
VT and its timing than patients with lower serum glucose 
levels, irrespective of a history of previously diagnosed 
diabetes, though there were inconsistencies in the risks 
observed according to baseline levels of serum glucose.
Table 2 Serum glucose levels at  the  time of  hospital admission for  acute myocardial infarction and  development 
of ventricular tachycardia (VT)
Italic values indicate significance of p value (p < 0.05)
Early onset VT was defined as VT that occurred within 48 h after hospital admission
IR incidence rate
a Adjusted for age, sex, race, and history of diabetes
b Adjusted for age, sex, race, history of diabetes, and AMI type
c Adjusted for age, sex, race, and in-hospital development of heart failure
Type of VT VT (IR) Odd ratio (95% confidence interval)
Unadjusted Multivariable adjusted
< 140 mg/dl ≥ 140 mg/dl < 140 mg/dl ≥ 140 mg/dl
All episodes of VT 652 (15.7%) Reference 1.28 (1.08–1.51) Reference 1.48a (1.23–1.78)
Early onset VT 434 (10.5%) Reference 1.21 (0.99–1.48) Reference 1.39b (1.11–1.73)
Late onset VT 218 (5.32%) Reference 1.42 (1.07–1.87) Reference 1.19c (0.89–1.59)
Table 3 Serum glucose levels at the time of hospital admission for acute myocardial infarction (AMI) and development 
of ventricular tachycardia (VT) in select patient subgroups
Italic values indicate significance of p value (p < 0.05)
STEMI ST segment-elevation myocardial infarction, NSTEMI non-ST segment-elevation myocardial infarction, n subsample
|Adjusted for age, sex, and race
Population VT/n Odd ratio (95% Confidence interval)
Unadjusted Multivariable adjusted|
< 140 mg/dl ≥ 140 mg/dl < 140 mg/dl ≥ 140 mg/dl
Diabetes status
 Diabetic 216/1494 Reference 1.66 (1.11–2.47) Reference 1.72 (1.15–2.57)
 Nondiabetic 436/2646 Reference 1.36 (1.10–1.67) Reference 1.41 (1.14–1.74)
AMI type
 STEMI 281/1277 Reference 1.17 (0.90–1.53) Reference 1.32 (1.00–1.73)
 NSTEMI 371/2863 Reference 1.33 (1.07–1.66) Reference 1.30 (1.04–1.63)
Table 4 Risk of developing ventricular tachycardia (VT) during hospitalization for acute myocardial infarction according 
to hospital admission serum glucose levels and history of diabetes
Serum glucose 
levels (mg/dl)
Diabetes previously diagnosed (+) % developing Diabetes not previously diagnosed (−) % developing
n All episodes 
of VT
Early onset VT Late onset VT n All episodes 
of VT
Early onset VT Late onset VT
< 120 185 9.7 6.5 3.2 996 13.7 9.8 3.8
120–139 132 10.6 6.1 4.6 636 16.7 11.0 5.7
140–159 129 20.9 14.0 7.0 382 17.5 12.6 5.0
160–179 136 22.8 14.7 8.1 235 20.9 13.2 7.7
> 180 912 13.8 8.2 5.6 397 19.7 13.6 6.1
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Discussion
We found that patients with elevated serum glucose lev-
els at the time of hospital admission for an AMI were 
at considerably greater risk for developing VT during 
their hospitalization, most notably early during their 
acute hospital stay, than patients with normoglycemia. 
This association was observed in both diabetic and non-
diabetic patients and in patients with a STEMI and an 
NSTEMI.
Serum glucose levels and the risk of developing VT
Elevated serum glucose levels at the time of hospital 
admission for AMI have been associated with higher 
death rates in both diabetic and nondiabetic patients [26]. 
However, supportive evidence for an association between 
hyperglycemia and developing a serious cardiac arrhyth-
mia, especially VT, is limited. In our large community-
based study we found an elevated risk for developing VT 
among AMI patients with serum glucose levels ≥ 140 mg/
dl.
Our findings are consistent with those of a limited 
number of prior studies, despite their small sample 
sizes [21], non-optimal reperfusion treatment [10, 11], 
and failure to examine the relation between hyperglyce-
mia and the time of onset of VT [10, 12]. In a study of 
1258 consecutive patients with AMI admitted to a single 
coronary care unit in Valencia, Spain over a 4-year study 
period, patients with elevated serum glucose levels at the 
time of hospital admission had more than twice the odds 
of developing either VT or ventricular fibrillation than 
patients with lower serum glucose levels [10].
Several mechanisms have been proposed to explain 
the potentially proarrhythmic effects of hyperglycemia 
in patients hospitalized with an AMI. Hyperglycemia 
can cause QT-interval prolongation and dispersion [27], 
which can trigger ventricular arrhythmias in those with 
underlying coronary artery disease [28]. Hyperglycemia 
has been associated with a larger infarct size, worse left 
ventricular function [26, 29], and increases in serum bio-
markers of inflammation [25, 29] each of which may pro-
mote the development of secondary cardiac arrhythmias. 
Hyperglycemia following an ischemic injury may also be 
a proxy of increased sympathetic activity, which could 
exert its proarrhythmic effects through elevated circula-
tory catecholamines and free fatty acids [30].
Irrespective of the underlying mechanisms involved, 
the greater risk of developing VT among AMI patients 
with elevated glucose levels emphasizes the need for sys-
tematically assessing serum glucose levels at the time of 
hospital admission and for more aggressive surveillance 
and treatment of patients with elevated glucose levels to 
reduce their risk of developing VT.
Association of elevated serum glucose levels and timing 
of VT
After adjusting for several potentially confounding vari-
ables, we found that patients with hyperglycemia were at 
increased risk for developing early VT. Early VT may be 
triggered by increased sympathetic activity or the inflam-
matory response to acute ischemic injury, each of which 
have been shown to be associated with elevated serum 
glucose levels in patients with AMI [31]. Inflammatory 
responses to the acute ischemic insult predominately 
occur during the first few days after an AMI and are asso-
ciated with increased resting membrane potential and 
prolonged action potential duration [25, 29], which may 
contribute to the triggering of early onset VT [32].
While coronary reperfusion therapy may induce rep-
erfusion-associated cardiac arrhythmias, and may have 
contributed to some of the cases of early VT observed 
in the present investigation, adjusting for the receipt of 
coronary reperfusion therapy did not materially change 
the estimated association of hyperglycemia with the risk 
of developing VT.
Hyperglycemia was also associated with a higher like-
lihood of developing late VT, a condition that usually 
occurs due to reentry pathways via isolated bundles of 
surviving myocytes at the border of the infarct [33]. Late 
VT may also occur secondarily to developing heart fail-
ure or cardiogenic shock [26], which may be more prev-
alent in patients with a larger acute infarct, that is also 
associated with the hyperglycemic state [34].
In the present study, the elevated risk for developing 
late VT in patients with hyperglycemia was modestly 
attenuated after adjusting for heart failure and other 
potentially confounding factors of prognostic impor-
tance. These findings suggest that hyperglycemia may 
act by worsening left ventricular function to promote the 
onset of late VT. Inasmuch, efforts to reduce infarct size 
and improve left ventricular function may reduce the late 
proarrhythmic effects of hyperglycemia.
Risk of VT in diabetic and nondiabetic patients 
with elevated serum glucose levels
At the time of hospital admission, patients with diabetes 
had higher serum glucose levels than patients without 
this metabolic disorder. However, these higher average 
glucose levels did not translate into a greater risk for 
developing VT. Several prior studies have also reported 
that, compared to patients without diabetes, patients 
with diabetes had a similar risk of developing new onset 
ventricular arrhythmias [10, 35].
In separate analyses for patients with and without pre-
viously diagnosed diabetes, we found that serum glucose 
levels ≥ 140 mg/dl at admission were associated with an 
Page 7 of 9Tran et al. Cardiovasc Diabetol          (2018) 17:136 
increased risk of developing VT. Our results are consist-
ent with the findings in the large Korea Acute Myocar-
dial Infarction Registry-National Institutes of Health 
(KAMIR-NIH) registry of 12,625 patients with AMI [2]. 
In this registry, the risk of developing VT was higher 
among patients who had glucose levels > 200  mg/dl at 
the time of hospital admission than patients who had 
lower serum glucose levels [36]. On the other hand, the 
aforementioned study in Spain, similar associations were 
observed only among patients without, but not those 
with, a history of diabetes [10]. However, the authors 
of that study used a liberal cutoff of 180 mg/dl to define 
hyperglycemia and the risk of VT primarily increased 
when serum glucose levels were higher than 120  mg/dl 
in patients with diabetes. Inasmuch, high risk patients 
might have been included in the two comparison groups 
[10].
Elevated sympathetic activity and acute inflammatory 
processes may play a larger role in inducing VT after 
AMI rather than the effects of chronic high concentra-
tions of glucose itself. Analysis of the Hyperglycemia: 
Intensive Insulin Infusion In Infarction (HI-5) study 
showed that the ratio of serum glucose levels at the time 
of hospital admission, to average glucose levels dur-
ing the prior 24  months, which also took into account 
patients prior history of diabetes, was associated with a 
higher risk of developing serious cardiac arrhythmias 
[37]. This hypothesis may also help to explain the signifi-
cant association that we observed between hyperglyce-
mia and the development of early, but not late, VT when 
sympathetic activation and the inflammatory response 
may subside. It is also possible that the antidiabetic thera-
pies that patients with a history of diabetes might have 
received could have prevented or mitigated the onset of 
VT. However, these hypotheses remain speculative and 
warrant further investigation.
Risk of VT in patients with STEMI and NSTEMI with elevated 
serum glucose levels
Consistent with the results of prior studies [38], we 
found that VT occurred more frequently in patients with 
a STEMI than in those with an NSTEMI (22% vs. 13%). 
This may be due to the complete blockage of a coronary 
artery that occurs in patients with a STEMI and the sub-
sequent development of hemodynamic disturbances and 
myocardial electrical instability. In the present study, 
when the study sample was further stratified according 
to the presence of the type of AMI, patients with hyper-
glycemia experienced a 30% elevated odds of developing 
VT during their acute hospitalization. We are not aware 
of any previous study that has examined the relationship 
between elevated serum glucose levels and the risk of 
developing VT according to the two principal phenotypic 
expressions of AMI. The increased risk of VT associated 
with hyperglycemia suggests that close monitoring and 
treatment of hyperglycemia may reduce the risk of VT in 
patients with who are hospitalized with either a STEMI 
or an NSTEMI.
Study strengths and limitations
The present study has several strengths. We used data 
from a large, population-based, investigation of patients 
hospitalized with AMI at all medical centers in cen-
tral Massachusetts, all of whom were telemonitored for 
their entire hospital stay, thereby minimizing the pos-
sibility of undiagnosed asymptomatic VT. However, 
some limitations of our observational study need to be 
acknowledged. The in-hospital management of patients 
with hyperglycemia may affect the development of VT, 
especially late VT; however, we were unable to examine 
the impact of anti-hyperglycemic treatment since we 
did not collect data on the use of insulin or other anti-
diabetic medications. We did not collect any information 
on changes in serum glucose levels during hospitaliza-
tion for AMI, and, therefore, could not characterize the 
persistence of hyperglycemia throughout a patient’s 
acute hospitalization. We also did not collect informa-
tion about patient’s serum glycated hemoglobin levels 
for purposes of examining the effects of acute versus 
chronic hyperglycemia on the development of VT. Lastly, 
we did not collect information about the sustainability 
of VT. Inasmuch, we could not examine the relationship 
between hyperglycemia with sustained and nonsustained 
VT separately.
Conclusions
Patients with elevated serum glucose levels were at 
increased risk for developing VT, especially within the 
first 48 h after hospital admission, among patients hospi-
talized with validated AMI at all medical centers in cen-
tral Massachusetts. Further studies are needed to more 
fully understand both the biologic mechanisms involved 
in the associations observed and the effects of hospital 
therapies that reduce serum glucose levels on the risk of 
developing VT following an AMI.
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